Hussman Strategic Advisors’s Pacira BioSciences PCRX Stock Holding History

Hussman Strategic Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-126,000	Closed	-$3.26M	–	318
2025 Q4	$3.26M	Buy	126,000 +21,000	+20%	+$499K	0.79%	16
2025 Q3	$2.71M	Buy	+105,000	New	+$2.58M	0.59%	48
2024 Q4	–	Sell	-21,000	Closed	-$316K	–	290
2024 Q3	$316K	Hold	21,000	–	–	0.08%	181
2024 Q2	$601K	Hold	21,000	–	–	0.17%	181
2024 Q1	$614K	Hold	21,000	–	–	0.14%	175
2023 Q4	$709K	Sell	21,000 -5,000	-19%	-$146K	0.16%	172
2023 Q3	$798K	Hold	26,000	–	–	0.15%	222
2023 Q2	$1.04M	Sell	26,000 -20,800	-44%	-$860K	0.19%	211
2023 Q1	$1.91M	Hold	46,800	–	–	0.3%	138
2022 Q4	$1.81M	Buy	+46,800	New	+$2.28M	0.29%	138
2022 Q1	–	Sell	-5,200	Closed	-$313K	–	345
2021 Q4	$313K	Sell	5,200 -1,000	-16%	-$55.1K	0.07%	277
2021 Q3	$347K	Sell	6,200 -6,200	-50%	-$357K	0.08%	269
2021 Q2	$752K	Buy	+12,400	New	+$785K	0.16%	224

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Hussman Strategic Advisors's PCRX Position: Q1 2026 in Review

Hussman Strategic Advisors sold out of Pacira BioSciences (PCRX) in Q1 2026, closing a stake of 126,000 shares — an estimated $3.26M sold.

Hussman Strategic Advisors first reported a position in PCRX in Q2 2021 and held it in 13 quarters. The position peaked at $3.26M in Q4 2025. 242 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.

Hussman Strategic Advisors reported no remaining Pacira BioSciences position as of Q1 2026 after selling out during the quarter.
Hussman Strategic Advisors sold 126,000 Pacira BioSciences shares in Q1 2026, an estimated $3.26M.
Hussman Strategic Advisors first reported a position in Pacira BioSciences in Q2 2021 and held it in 13 quarters.
Hussman Strategic Advisors's Pacira BioSciences position peaked at $3.26M in Q4 2025.
242 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.

Based on Hussman Strategic Advisors's 13F filing for Q1 2026, filed 11 May 2026.